Login / Signup

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Hermann EichlerPantep AngchaisuksiriKaan KavakliPaul KnoeblJerzy WindygaVictor Jiménez-YustePhilip Harder DelffPratima Chowdary
Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
Concizumab phase 2 trials will target an exposure ≥100 ng/mL, with a once-daily regimen.
Keyphrases
  • electronic health record
  • physical activity
  • big data
  • human health
  • data analysis
  • climate change